Kazia Therapeutics (NASDAQ:KZIA) is an oncology-focused biotechnology company developing treatments for various forms of cancer. Its main drug candidate is paxalisib, which is being studied for its effectiveness against brain, colorectal, and breast cancers. The company's progress has attracted positive attention from market analysts.
On September 1, 2026, analyst firm BTIG maintained its Buy rating for Kazia Therapeutics. The firm also increased its price target on the stock to $40.00, a significant rise from the previous target of $34.00. At the time of the rating, the stock's price was $12.79, suggesting a strong belief in the company's future performance.
This analyst optimism follows positive new data on paxalisib. In a preclinical model for a type of colorectal cancer, the drug reduced tumor burden by 52%. The company reports that paxalisib is well tolerated and is now preparing to advance it into a Phase 2 clinical study for this cancer type.
Kazia Therapeutics also announced promising preclinical data for paxalisib in treating HR+/HER2- breast cancer. The findings show the drug helps make tumors that are resistant to standard therapy responsive again. As a result, the company is expanding its ongoing breast cancer clinical trial to include this patient group, with the first patient expected by year-end 2026.
As highlighted by PRNewsWire, Kazia Therapeutics recently closed a public offering that generated approximately $40.00 million in upfront proceeds. The offering includes milestone-linked warrants, which are options for investors to buy more shares at set prices if the company achieves specific clinical goals. Kazia Therapeutics shares are currently trading at $13.07, giving the company a market capitalization of about $21.17 million.
